Artiva Biotherapeutics Appoints Diego Miralles as President & Head of R&D
Artiva Biotherapeutics, Inc. announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings over two decades of senior leadership and drug development experience, with a proven track record of advancing therapies from discovery through FDA approval and commercialization. His expertise will be crucial as Artiva advances its lead program, AlloNK®, in autoimmune diseases and prepares for a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026, with a goal to file the first BLA for AlloNK in 2029. In connection with his appointment, Dr. Miralles received an inducement grant of options to purchase 232,500 shares and 77,500 restricted stock units.
Key Highlights
- Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of Research and Development.
- Dr. Miralles brings over 20 years of leadership experience in research, clinical development, and commercialization.
- He previously served as CEO of Laronde Inc. and Vividion Therapeutics, and global head of Johnson & Johnson Innovation.
- He was granted options to purchase 232,500 shares of Artiva's common stock.
- He was also granted 77,500 restricted stock units (RSUs).
- The inducement grants will vest over four years, with 25% vesting on May 15, 2027.
- Artiva plans to initiate a Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis in 2026.
- The company aims to file its first successful BLA for AlloNK in 2029.
Price Impact
More from ARTV